RESEARCH – In an opinion published on Friday January 14, experts from the World Health Organization recommend two new treatments against Covid-19, sotrovimab and baricitinib. However, they should not be administered to just any patient.
The editorial staff of LCI with AFP –
Three and two make five. The World Health Organization (WHO) officially recommended, on Friday January 14, two new treatments against Covid-19 in very specific cases, for a total now increased to five. In an opinion published in the medical journal The BMJ, experts from the specialized agency of the UN recommend treatment with synthetic antibodies, sotrovimab, and a drug usually used against rheumatoid arthritis, baricitinib.
All the info on
Variant Omicron: the planet on high alert
Both are not intended for just any patient. Sotrovimab is recommended for those who have contracted mild Covid but are at high risk of hospitalization. Its benefit for those not at risk is considered too low. Baricitinib is recommended for “patients with severe or critical Covid”, to which it should be administered “in combination with corticosteroids”. That “improves survival rates and reduces the need for mechanical ventilation”.
A limited therapeutic arsenal
Anti-Covid treatment recommendations are regularly updated, based on clinical trials conducted on different types of patients. However, the therapeutic arsenal remains limited. In recent months, the WHO has rejected the use of several treatments: the injection of plasma from patients cured of Covid, ivermectin and hydroxychloroquine. The UN agency recommended only three treatments: synthetic antibodies sold under the name Ronapreve, since September 2021, a class of drugs called “interleukin 6 antagonists” (tocilizumab and sarilumab), since July 2021 , and the systematic use of corticosteroids for severely affected patients, since September 2020.
- Covid-19: can doctors prescribe “only Doliprane” to patients?
- Covid-19: what do we know about the antiviral drug Molnupiravir, first promising then rejected by the HAS?
Sotrovimab concerns the same type of patients as Ronapreve. “Their efficacy against new variants like Omicron is still uncertain”, however, are nuanced by WHO experts. Similarly, baricitinib “has the same effects” as interleukin-6 antagonists, and should be administered to the same patients. “When Both Are Available”, it is therefore necessary to choose which of the two to use “depending on cost, availability and caregiver experience”, they recommend.
In addition, baricitinib belongs to a family of drugs called “Janus kinase inhibitors” and used against rheumatoid arthritis, an autoimmune disease. However, ruxolitinib and tofacitinib should not be used, say WHO experts, due to lack of data on their efficacy or side effects.
On the same subject
The most read articles
Parties the day before Prince Philip’s funeral: Downing Street apologizes to Queen Elizabeth II
Epstein case: Prince Andrew loses his title of royal highness and his military honors
American diplomats in Paris and Geneva in turn affected by the mysterious “Havana syndrome”
EXCLUSIVE – Presidential 2022: discover the results of our daily survey of January 14
VIDEO – The Livret A rate will double, announces Bruno Le Maire on TF1
defends the ambition of information
verified and accessible to all thanks to the income of the
To help us keep this service free you can “change your choice” and accept all cookies.
EDIT AND ACCEPT ALL